Development Strategies For Difficult To Express Proteins

Sponsored by: Catalent Pharma Solutions

Focused on:

  • Antibody Platforms
  • Proteins
  • Cell Line Development
  • Complex Biopharmaceuticals

Date: 12 June


Time: 5PM London/12PM New York

Cell line development strategies for difficult to express proteins

Biopharmaceutical products in development continue to increase in complexity. These include numerous multi-specific antibody platforms, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, as well as unique protein fusions and various protein conjugates. Many of these types of molecules require multiple proteins to be expressed at differing ratios to get the correct biopharmaceutical produced at maximum titer and quality.

New cell line development methodologies as well as new instrumentation are enabling these complex programs to be performed more efficiently. In this webinar, we outline two successful case studies taking complex biopharmaceuticals to clinical production and how the Beacon® platform for clonal cell line selection and the use of ambr® bioreactor systems will help improve development timelines and the quality of the cell lines for these types of molecules.

Presented by

Gregory Bleck, PHD,

Global Head of R&D, Biologics

Gregory Bleck is Global Head of Research and Development at Catalent Biologics with overall responsibility for development and acquisition of new products and technologies. Dr. Bleck has over 20 years in biopharma R&D. He received his BS and PhD from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign working in the areas of gene regulation and expression. At Catalent, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx® process. Dr. Bleck has published over 60 research papers and authored three book chapters. He has 14 issued patents and eight patents currently under review. His work at the University of Illinois was recently highlighted in a book about the greatest advances in the first 150 years of innovation at the University.

Tanner Nevill, PhD,

VP, Product Applications

Tanner Nevill is Vice President of Product Applications at Berkeley Lights. Working with multidisciplinary teams of scientists and engineers, he has played a key role in the development of many of the company’s core technologies, specifically how they can be applied to antibody discovery and cell line development. Tanner obtained his Ph.D. in
bioengineering from UC Berkeley and previously held positions at GlaxoSmithKline and Fluxion Biosciences. With over a dozen publications and over two dozen patents, Tanner has been involved in life science technology and product development for over 12 years.

Key Learning Objectives

  • Understand the key challenges associated with developing complex and non-traditional antibody-based biologics
  • Learn about new technologies that improve the robustness of cell line and process development platforms
  • Review data that compares expression levels of complex biologics utilizing different development methods
  • Uncover other benefits, besides increased titer, that can be achieved by utilizing these strategies


  • Scientific Officer
  • Process Development Scientist
  • CMC Engineer
  • Bioprocessing Engineer
  • Upstream Development Scientist
  • Downstream Development Scientist
  • CEO
  • VP of Biologic Development
  • Consultant
  • VP of Bioprocessing
  • VP of Process Development
  • VP of Biomanufacturing
  • Director of Biologic Development
  • Director of Bioprocessing
  • Director of Process Development
  • Director of Biomanufacturing
  • VP of Bioproduction
  • Director of Bioproduction
  • Director of Biologics